



## Separation and Study of Some Kinetic Properties of Senescence Marker Protein -30 in Human Plasma

Luay A. Al-Helaly

Maryam A. Saleh

*Department of Chemistry  
College of Science  
University of Mosul*

### ABSTRACT

The research includes the isolation of senescence marker protein-30 (SMP-30) from human plasma of normal young male age 25 year, the factors affecting the activity of the enzyme and determination of its molecular weight. One band had been isolated by gel filtration chromatography from the proteinous supernatant produced by precipitation by ammonium sulfate (60%) after dialysis and separation by cooling centrifuge. Apparent molecular weight of the isolated enzyme using gel filtration chromatography was (34672) Dalton.

The results also showed that the optimum conditions of SMP-30 activity were obtained at (100 µg/ml) of enzyme concentration and phosphate buffer (0.022 mol/l) as a buffer at pH (8) for (18) minutes at (49°C) using (14 mmol/l) of gluconolactone (GL) as a substrate,. Using Line Weaver–Burk plot, the values of maximum velocity ( $V_{max}$ ) and Michaelis constant ( $K_m$ ) were (0.65 µmol/ min) and (5.6 mmol/l) respectively. Beside of, the study showed the inhibition effect of some chemicals and drugs on the enzyme activity, Phenylphrine, neomycin and mercuric chloride possessed a noncompetitive inhibition and anhydrous caffeine possessed a competitive inhibition and arsenate meta sodium possessed a uncompetitive.

**Keywords:** Senescence marker protein-30(SMP-30), Gluconolactonase (GNL).

(Senescence marker protein-30(SMP-30)) 30-

1992

34

SMP-30 (Maruyama *et al.*, 2010)

(Tabun Sarin Soman : )

SMP-30 (Billecke *et al.*, 1999; Kondo *et al.*, 2004; Arun *et al.*, 2011)

SMP-30

Protein phosphatase

Protein kinase

(Yamaguchi, 2005)

RNA DNA

SMP-30 .(Son *et al.*, 2006)

(Fujita, 1999; Fujita *et al.*,1999)

:

Aging

SMP-30 .(Feng *et al.*, 2004)

.(Ishigami *et al.*, 2002) Apoptosis

factor

(EC 3.1.1.17) Gluconolactonase (GNL)




SMP-30

Gluconate

Gluconolactone (GL)

:

(Chakraborti and Bahnson, 2010)



**Gluconolactone**

**Gluconate**

(Bublitz and Lehninger , 1961)

Ascorbic acid metabolism

.(Kondo *et al.*, 2006) Caprolactam degradation

SMP-30

:

**Protein precipitation by salting out .1**

%60

(Robyte and White, 1987)

° 4

60

24

**Cooling centrifuge separation .2**

)

40

13000 xg

(

/

/

Modified Lowry method

SMP-30

.(Schacterle and Pollack, 1973)

-20°C

**Dialysis ( ) .3**

10

7.2

°4

(Boyer, 2000) /

12

48

**Gel filtration chromatography .4**

2.6 × 93

100

(Sephadex G-100) G-100

76

)

(

.(Murray *et al.*, 2009)

:

(Trp.)

3

( )

Blue dextran

Internal volume (V<sub>i</sub>)

) SMP-30

Void volume (V<sub>o</sub>)

Pepsin Egg albumin Bovine serum albumin(BSA)  
 10 ( ) 0.1 .(Papain  
 5

3 / 60 .Elution solution  
 Fraction collector

280

SMP-30

**Lyophilizer .5**

SMP-30

**:SMP-30/GNL**

SMP-30

(GNL)

: (Hucho and Wallenfels, 1972) SMP-30

10 pH 7.2 -1

10 P-nitrophenol 0.25 -2

10 Gluconolactone -3

30 3 0.99 -4

405 ° 24

° 37

(1)

( 14000 )

.(Berg *et al.*, 2007)

:

( )

Sephadex G-100

SMP-30

229.4

(1)

(1)

(1)

25 SMP-30 :1


%	( )	( / )	( )	( / ) *	( / )	( )	
100	1.0	0.00177	15.4	0.154	87.0	100	
62.2	1.2	0.00207	9.58	0.168	81.0	57	60%
12.5	0.3	0.00058	1.92	0.04	69.0	48	
77	1.8	0.0031	11.86	0.177	57.0	67	
46.4	8.0	0.0141	7.15	0.11	7.8	65	

/

SMP-30

:

\*



SMP-30

: 1

:

( 2000000 - 204)

(2) (V<sub>o</sub>) (V<sub>i</sub>)  
(Sephadex G-100)

:2

**.Sephadex G-100**

( )	( )	
127.3	2000000	<b>Blue dextran</b> (V <sub>o</sub> )
130.8	67000	<b>Bovine serum albumin</b>
162.9	45000	<b>Egg albumin</b>
223.1	36000	<b>Pepsin</b>
298.7	21000	<b>Papain</b>
409.2	204	(V <sub>i</sub> ) <b>Tryptophan</b>
<b>229.4*</b>	<b>34672</b>	( )

(1)

\*


30-

(2)

34672

SMP-30

(Kondo *et al.*, 2006; Fujita *et al.*,1992)



: 2

SMP-30

(pH)( )

(Murray et al., 2009).

.1

SMP-30

(3)

( / 120-20)

/ 100

.2

.1.2

7.2

( / 0.03-0.002)

.(4)

( / 0.022)

:

.2.2

(pH)

.Optimum pH

/ 0.022

SMP-30



.8

(5)

:

.3

(6)





: 4

SMP-30

: 3

.SMP-30



SMP-

: 6

:5

30

.SMP-30

.4 :


( ) Optimum temperature  
Denaturation

SMP-30

(Boyer, 2000)

(7)

°49



.SMP-30

: 7

.5 :

(Berg *et al.*,2007) ( $V_{max}$ )

(GL)

(8) / 26 - 2


( $V_{max}$ )

(Murray *et al.*, 2009)


$$GL \quad / \quad 14 \quad (8)$$

$(V_{max})$  (Line Weaver-Burk plot) -

$$:(9) \quad / \quad 5.6 \quad / \quad 0.65 \quad SMP-30 \quad (K_m)$$



(GL) : 8



$$.(K_m) \quad (V_{max}) \quad - \quad : 9$$

:SMP-30 .6

SMP-30

: .1.6

( / 16 14 12)

.(3) .SMP-30



:( )

.2.6

(4) SMP-30  
( / 16 14 12)

Flagyl

Chloramphenicol

Ceramide )

(Horak *et al.*, 2009; Falagas *et al.*, 2008) (Neomycin(Pacher *et al.*, 2006) Allopurinol(Nehlig *et al.*, 1992)

(Jenner and Marsden, 1979) Metoclopramide

) Paracetamol

Pseudoephedrine (Horak *et al.*, 2009) Phenylphrine

Theophylline anhydrous (Brunton, 2006)

.(Yoshikawa, 2007)

.(7 )

(4)

25

SMP-30

**.SMP-30**

**: 4**

*	SMP-30	( / )	
42.3	0.377	12	<b>Metoclopramide</b>
44.3	0.364	14	
49.4	0.331	16	
35.9	0.419	12	<b>Chloramphenicol</b>
39.3	0.397	14	
53.8	0.302	16	
42.2	0.378	12	<b>Paracetamol</b>
58.4	0.272	14	
74.9	0.164	16	
63.7	0.237	12	<b>Anhydrous theophylline</b>
64.5	0.232	14	
65.4	0.226	16	
69.5	0.198	12	<b>Anhydrous caffeine</b>
54.77	0.294	14	
50.1	0.324	16	
69.6	0.199	12	<b>Phenylphrine</b>
71.4	0.186	14	
75.2	0.162	16	
74.3	0.168	12	<b>Flagyl</b>
77.2	0.149	14	
90.06	0.065	16	
55.6	0.29	12	<b>Ceramide</b>
58.7	0.27	14	
66.05	0.222	16	
54.4	0.298	12	<b>Pseudephedrine</b>
60.09	0.261	14	
64.8	0.23	16	
87.4	0.082	12	<b>Neomycin</b>
88	0.078	14	
91.5	0.055	16	
52.7	0.309	12	<b>Allopurinol</b>
57.03	0.281	14	
57.6	0.277	16	

. / (0.65)

\*

**: SMP-30**

**.7**


**:**

**.1.7**

**.(10)**

**/**

**8**



.SMP-30 : 10


.Noncompetitive

(11).

(Murray et al., 2009)

$K_m$


$V_{max}$



: 11

.2.7

(12).



SMP-30


: 12

Uncompetitive

$K_m$

(13)

(Murray et al., 2009)  $V_{max}$




: 13

3.7

/ 16

(14)

20



.SMP-30 : 14

Competitive


(GL)

$V_{max}$

$K_m$

(15)


(Murray et al., 2009)



: 15

.4.7

(16) ( / 12)



.SMP-30


: 16

.Noncompetitive

.(17)

$K_m$


$V_{max}$



: 17

: 5.7

.(18)




.SMP-30

: 18

$K_m$

$V_{max}$

Noncompetitive



: 19

:SMP-30

.8

(5)

SMP-30

:

: 5

( / )	( ° )	( / )		( )	( / )
14	49	0.022	8	18	100

- Arun, P.; Aleti, V.; Parikh, K.; Manne, V.; Chilukuri, N. (2011). Senescence marker protein 30 (SMP30) expression in eukaryotic cells: existence of multiple species and membrane localization. *PLoS ONE*. **6**(2), 16545.
- Berg, J. M.; Tymoczko, J. L.; Stryer, L. (2007). "Biochemistry" W. H. Freeman and Company". New York, USA. pp.138,139,145,146,149, 687.
- Billecke, S.S.; Primo-Parmo, S.L.; Dunlop, C.S.; Doorn, J.A.; La Du, B.N.(1999). Characterization of a soluble mouse liver enzyme capable of hydrolyzing di iso propyl phosphorofluoridate. *Chem. Biol. Interact.* **19**(120), 251-256.
- Boyer, R.(2000). "Modern Experimental Biochemistry". 3rd ed. Addison Wesley Longman, USA. pp.52,71.
- Brunton, L. L.(2006)."Goodman and Gilman's .The Pharmacological Basis of Therapeutics". (11th ed.). New York: McGraw-Hill Medical Publishing Division.
- Bublitz, C.; Lehninger, A.L. (1961). The role of aldonolactonase in the conversion of L-gulonate to L-ascorbate. *Biochim. Biophys. Acta* **47**, 288–297.
- Chakraborti, S.; Bahnson, B. J. (2010). Crystal structure of human senescence marker protein 30; insights linking structural, enzymatic and physiological functions. *Biochemistry*. **49**(16), 3436-3444.
- Falagas, M. E.; Grammatikos, A. P.; Michalopoulos, A. (2008). Potential of old-generation antibiotics to address current need for new antibiotics. *Expert Review of Anti Infective Therapy*, **6** (5), 593–600.
- Feng, D.; Kondo, Y.; Ishigami, A.; Kuramoto, M.; Machida, T. (2004). Senescence marker protein-30 as a novel anti aging molecule. *Ann. N. Y. Acad Sci* . **1019**,360-364.
- Fujita, T. (1999).Senescence marker protein-30(SMP-30) :Structure and biological function. *Bio chem. Biophys. Res. Commun.* **254**, 1-4.
- Fujita, T.; Shirasawa, T.; Maruyama, N. (1999). Expression and structure of senescence marker protein-30(SMP-30) and its biological significance. *Mech. Aging Dev.* **107**, 271-280 .
- Fujita, T.; Uchida, K.; Maruyama, N.(1992). Purification of senescence marker protein-30 (SMP30) and its androgen-independent decrease with age in the rat liver. *Biochim. Biophys. Acta* **1116**, 122-128.
- Horak, F.; Zieglmayer, P.; Zieglmayer, R.; Lemell, P.; Yao, R.; Staudinger, H.; Danzig, M. (2009). A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber. *Annals of Allergy, Asthma and Immunology*. **102** (2), 116.

- Hucho, F. ; Wallenfels, K. (1972). Glucono-d-lactonase from *Escherichia coli*. *Biochem. Biophys/ Acta* **276**, 176–179.
- Ishigami, A.; Fujita, T.; Handa, S.; Shirasawa, T.; Koseki, H.; Kitamura, T.(2002). Senescence marker protein-30 knockout mouse liver is highly susceptible to tumor necrosis factor-alpha- and Fas-mediated apoptosis. *Am. J. Pathol.* **161**, 1273–1281
- Jenner, P. ; Marsden, C.D. (1979). The substituted benzamides: a novel class of dopamine antagonists. *Life Sci.* **25** (4), 79-85.
- Kondo, Y.; Inai, Y.; Sato, Y.; Hando, S.; Kubo, S., (2006). Senescence marker protein 30 function as glucono lactonase in L-ascorbic acid biosynthesis, and its knock out mice are prone to scurvy. *Proc. Natl. Acad. Sci.* **103**, 5723-5728.
- Kondo, Y.; Ishigami, A.; Kubo, S.; Hando, S.; Gomi, K.(2004). Senescence marker protein - 30 is a unique enzyme that hydrolyzes di iso propyl phosphorofluoridate in the liver. *FEBS Lett.* **570**, 57-62.
- Maruyama, N.; Ishigami, A.; Kondo, Y. (2010). Pathophysiological significance of senescence marker protein-30. *Geriatr Gerontol Int* .**10**(1), S88-S98.
- Murray, R. K.; Bender, D. A., Botham, K. M.; Kennelly, P. J.; Rodwell, V. W. (2009). "Harper's Illustrated Biochemistry". 28 ed. The McGraw-Hill Companies, Chapter 8.
- Nehlig, A.; Daval, J. L.; Debry, G. (1992). Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. *Brain Research Reviews.* **17** (2), 139 –170.
- Pacher, P.; Nivorozhkin, A; Szabó, C. (2006). Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol. *Pharmacological Reviews.* **58** (1), 87–114.
- Robyt, F. J.; White, J. B. (1987). "Biochemical Techniques Theory and Practice". Books / Cole Publishing Com., USA.p.33.
- Schacterle, G. R.; Pollack, R. L. (1973). A simplified method for the quantitative assay of small amount of protein in biological material. *Anal. Biochem.* **51**, 654-655.
- Son, T.G.; Zou, Y.; Jung, K.J.; Yu, B.P.; Ishigami, A., (2006). SMP-30 deficiency causes increased oxidative stress in brain. *Mech. Aging Dev.* **127**, 451-457.
- Yamaguchi, M. (2005). Role of regucalcin in maintaining cell homeostasis and function (review). *Int. J. Mol. Med.* **15**, 371-389.
- Yoshikawa, H. (2007). First-line therapy for theophylline-associated seizures. *Acta Neurol. Scand.* **115** (4 Suppl), 57–61.